SURMOUNT-1 tested tirzepatide in people with obesity but without diabetes, and the results stunned the medical community
One trial showed that two-thirds of patients on once-weekly semaglutide 2.4 mg (Wegovy, Novo Nordisk) regained their weight 1 year after stopping the medication
Understanding the mechanism behind sulfur burps empowers you to take targeted steps that reduce frequency and severity without stopping treatment
They are also why gastrointestinal side effects are common during therapy
These trials include more than 2,050 participants across diverse regions, and the first major results from TRANSCEND-T2D-1 are expected to be presented at the American Diabetes Association Scientific Sessions in June, then published in a peer-reviewed journal
Unfortunately, there is significant evidence to suggest that one of the most popular third-party testing labs does not use scientifically sound methodologies and, in some cases, has fabricated results
